Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.38M Sell
57,284
-2,569
-4% -$67.2K 0.11% 163
2026
Q1
$1.68M Buy
59,853
+11,046
+23% +$294K 0.16% 118
2025
Q4
$1.22M Sell
48,807
-232
-0.5% -$5.85K 0.12% 154
2025
Q3
$1.25M Buy
49,039
+13,584
+38% +$335K 0.13% 155
2025
Q2
$859K Buy
35,455
+2,828
+9% +$66K 0.09% 214
2025
Q1
$827K Buy
32,627
+1,065
+3% +$27.9K 0.1% 204
2024
Q4
$837K Sell
31,562
-19,373
-38% -$525K 0.09% 225
2024
Q3
$1.47M Buy
50,935
+4,605
+10% +$134K 0.17% 126
2024
Q2
$1.3M Buy
46,330
+15,994
+53% +$440K 0.26% 82
2024
Q1
$842K Buy
30,336
+6,404
+27% +$178K 0.17% 141
2023
Q4
$689K Sell
23,932
-2,535
-10% -$76.6K 0.12% 103
2023
Q3
$878K Buy
+26,467
New +$936K 0.29% 81

Other funds holding PFE

Norden Group's PFE Position: Q2 2026 in Review

Norden Group reduced its Pfizer (PFE) stake by 4.3% in Q2 2026, selling an estimated $67.2K and leaving 57,284 shares worth $1.38M. The position accounts for 0.11% of the portfolio, ranked #163.

Norden Group first reported a position in PFE in Q3 2023 and has held it in 12 quarters since. The position peaked at $1.68M in Q1 2026. 2,841 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Norden Group held 57,284 shares of Pfizer worth $1.38M as of Q2 2026.
  • Norden Group sold 2,569 Pfizer shares in Q2 2026, an estimated $67.2K.
  • Pfizer made up 0.11% of Norden Group's portfolio in Q2 2026, its #163 holding.
  • Norden Group first reported a position in Pfizer in Q3 2023 and has held it in 12 quarters since.
  • Norden Group's Pfizer position peaked at $1.68M in Q1 2026.
  • 2,841 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Norden Group's 13F filing for Q2 2026, filed 29 Jul 2026.